Anti-cancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.

Anti-cancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab / Tabernero, J., Chawla, S.P., Kindler, H., Reckamp, K., Chiorean, E.G., Azad, N.S., Lockhart, A.C., Hsu, C.P., Baker, N.F., Galimi, F., Beltran, P., Baselga, J.. - In: TARGETED ONCOLOGY. - ISSN 1776-2596. - 10:1(2015), pp. 65-76. [10.1007/s11523-014-0315-z]